Soquelitinib's 75% EASI-75 in Phase 1 AD fuels a multi-indication build; SIERRA1 readout determines whether the signal survives randomized scale

Corvus Pharmaceuticals is a clinical-stage company developing a targeted inflammatory disease drug for atopic dermatitis that is not yet approved.

Soquelitinib, an ITK inhibitor that blocks T-cell signaling to reduce type 2 inflammation in skin disease and T-cell lymphoma, posted 75% EASI-75 versus 20% placebo in a blinded Phase 1 atopic dermatitis cohort, with durable drug-free remissions. The thesis stands or falls on whether SIERRA1, the randomized Phase 2 in roughly 200 patients, replicates that signal at scale. The most important risk is that Phase 1 small-cohort data in dermatology has repeatedly failed to translate, and soquelitinib faces a direct ITK-class rival in bosakitug from Aclaris in the same indication.